INNOVIVA, INC. Cash and Restricted Cash
INNOVIVA, INC. (INVA) had Cash and Restricted Cash of $570.39 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $570.39M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $603.09M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $550.94M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $476.51M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $570.39M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $603.09M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $550.94M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $476.51M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $397.53M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $319.09M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $304.96M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $260.63M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $217.00M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $178.36M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $193.51M 10-K · filed 2026-02-25 |
| 2023-09-30 | $180.00M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $173.03M 10-Q · filed 2024-07-31 |
| 2023-03-31 | $144.05M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $291.05M 10-K · filed 2026-02-25 |
| 2022-09-30 | $300.83M 10-Q · filed 2023-11-01 |
| 2022-06-30 | $283.58M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $216.80M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $201.53M 10-K · filed 2025-02-26 |
| 2021-09-30 | $135.12M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $43.27M 10-Q · filed 2022-07-27 |
| 2021-03-31 | $282.89M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $246.49M 10-K/A · filed 2024-03-05 |
| 2020-09-30 | $479.19M 10-Q · filed 2021-10-27 |
| 2020-06-30 | $413.15M 10-Q · filed 2021-07-29 |
| 2020-03-31 | $351.98M 10-Q · filed 2021-04-28 |
| 2019-12-31 | $278.10M 10-K · filed 2023-02-28 |
| 2019-09-30 | $172.95M 10-Q · filed 2020-10-28 |
| 2019-06-30 | $141.95M 10-Q · filed 2020-07-29 |
| 2019-03-31 | $65.15M 10-Q · filed 2020-04-29 |
| 2018-12-31 | $62.42M 10-K/A · filed 2022-03-17 |
| 2018-09-30 | $48.62M 10-Q · filed 2019-10-30 |
| 2018-06-30 | $87.23M 10-Q · filed 2019-07-24 |
| 2018-03-31 | $27.14M 10-Q · filed 2019-05-01 |
| 2017-12-31 | $73.34M 10-K · filed 2021-02-25 |
| 2017-09-30 | $138.42M 10-Q · filed 2018-10-31 |
| 2016-12-31 | $118.02M 10-K · filed 2020-02-19 |
| 2015-12-31 | $159.18M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |